181 – 190 of 256
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2001
-
Mark
Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer
(
- Contribution to journal › Article
-
Mark
Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients
(
- Contribution to journal › Article
-
Mark
Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics
(
- Contribution to journal › Article
-
Mark
DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase) : association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients
(
- Contribution to journal › Article
-
Mark
Image cytometric Auer class-I identifies a real low risk group among lymph node negative premenopausal breast cancer patients
(
- Contribution to journal › Published meeting abstract
-
Mark
Histological grade, its three components and flow cytometric S-phase as prognostic markers in premenopausal women with node negative breast cancer
(
- Contribution to journal › Published meeting abstract
- 2000
-
Mark
Histologic grading in breast cancer--reproducibility between seven pathologic departments. South Sweden Breast Cancer Group
(
- Contribution to journal › Article
-
Mark
Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast
(
- Contribution to journal › Article
-
Mark
ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer
2000) In Annals of oncology : official journal of the European Society for Medical Oncology 11(12). p.1545-1550(
- Contribution to journal › Article
-
Mark
Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
(
- Contribution to journal › Article